Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C21H25ClN2O3.C6H6O3S |
Molecular Weight | 547.063 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OS(=O)(=O)C1=CC=CC=C1.OC(=O)CCCN2CCC(CC2)O[C@@H](C3=CC=C(Cl)C=C3)C4=CC=CC=N4
InChI
InChIKey=UDGHXQPQKQPSBB-BOXHHOBZSA-N
InChI=1S/C21H25ClN2O3.C6H6O3S/c22-17-8-6-16(7-9-17)21(19-4-1-2-12-23-19)27-18-10-14-24(15-11-18)13-3-5-20(25)26;7-10(8,9)6-4-2-1-3-5-6/h1-2,4,6-9,12,18,21H,3,5,10-11,13-15H2,(H,25,26);1-5H,(H,7,8,9)/t21-;/m0./s1
Bepotastine is a non-sedating, selective antagonist of the histamine 1 (H1) receptor. It belongs to the second-generation piperidine chemical class. It is a mast cell stabilizer and suppresses the migration of eosinophils into inflamed tissues. Bepotastine was approved in Japan for use in the treatment of allergic rhinitis and uriticaria/puritus in July 2000 and January 2002, respectively, and is marketed by Tanabe Seiyaku Co., Ltd. under the brand name Talion. It is available in oral and opthalmic dosage forms in Japan. The opthalmic solution is FDA approved since Sept 8, 2009 and is under the brand name Bepreve.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24191914 | https://www.ncbi.nlm.nih.gov/pubmed/9368705
Curator's Comment: Because of limited systemic absorption and poor
blood-brain barrier penetration, the incidence of drowsiness with oral bepotastine besilate is
low in comparison with other oral antihistamine products such as loratadine and cetirizine.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL231 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20735291 |
5.7 null [pIC50] | ||
Target ID: CHEMBL4794 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24980233 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | TALION Approved UseTALION is usually used to treat allergic rhinitis, hives and itch resulting from skin diseases. Launch Date2000 |
|||
Primary | BEPREVE Approved UseBEPREVE® (bepotastine besilate ophthalmic solution) 1.5% is a histamine H1 receptor antagonist indicated for the treatment of itching associated with signs and symptoms of allergic conjunctivitis. BEPREVE ® is a histamine H1 receptor antagonist indicated for the treatment of itching associated with allergic conjunctivitis. (1) Launch Date2009 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
99.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24105252/ |
19 mg single, oral dose: 19 mg route of administration: Oral experiment type: SINGLE co-administered: |
BEPOTASTINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
7.3 ng/mL |
0.75 μg 1 times / day multiple, ocular dose: 0.75 μg route of administration: Ocular experiment type: MULTIPLE co-administered: |
BEPOTASTINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
392.4 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24105252/ |
19 mg single, oral dose: 19 mg route of administration: Oral experiment type: SINGLE co-administered: |
BEPOTASTINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24105252/ |
19 mg single, oral dose: 19 mg route of administration: Oral experiment type: SINGLE co-administered: |
BEPOTASTINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
45% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24105252/ |
19 mg single, oral dose: 19 mg route of administration: Oral experiment type: SINGLE co-administered: |
BEPOTASTINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
45% |
0.75 μg 1 times / day multiple, ocular dose: 0.75 μg route of administration: Ocular experiment type: MULTIPLE co-administered: |
BEPOTASTINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022288s000_ClinPharm.pdf#page=15 Page: 15.0 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022288s000_ClinPharm.pdf#page=15 Page: 15.0 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022288s000_ClinPharm.pdf#page=15 Page: 15.0 |
no |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022288s000_ClinPharm.pdf#page=4 Page: 4.0 |
minimal | |||
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Effect of histamine on the permeability of the nasal mucosa in vivo. | 2003 Apr |
|
Evaluation of efficacy and sedative profiles of H(1) antihistamines by large-scale surveillance using the visual analogue scale (VAS). | 2008 Sep |
|
Novel functional aspect of antihistamines: the impact of bepotastine besilate on substance p-induced events. | 2009 |
|
Multiple H1-antihistamine-induced urticaria. | 2009 Apr |
|
Next-day residual sedative effect after nighttime administration of an over-the-counter antihistamine sleep aid, diphenhydramine, measured by positron emission tomography. | 2010 Dec |
|
Bepotastine (bepreve)--an ophthalmic H1-antihistamine. | 2010 Feb 8 |
|
Bepotastine besilate, a highly selective histamine H(1) receptor antagonist, suppresses vascular hyperpermeability and eosinophil recruitment in in vitro and in vivo experimental allergic conjunctivitis models. | 2010 Jul |
Patents
Sample Use Guides
For adults: In general, take 1 tablet (10 mg of the active ingredient) at a time, twice a day. The dose may be adjusted according to your disease, age and symptom.
For children aged 7 years and older: In general, take 1 tablet (10 mg of the active ingredient) at a time, twice a day.
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29578
Created by
admin on Fri Dec 15 16:04:20 GMT 2023 , Edited by admin on Fri Dec 15 16:04:20 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
WW-121
Created by
admin on Fri Dec 15 16:04:20 GMT 2023 , Edited by admin on Fri Dec 15 16:04:20 GMT 2023
|
PRIMARY | |||
|
DTXSID80172577
Created by
admin on Fri Dec 15 16:04:20 GMT 2023 , Edited by admin on Fri Dec 15 16:04:20 GMT 2023
|
PRIMARY | |||
|
C511534
Created by
admin on Fri Dec 15 16:04:20 GMT 2023 , Edited by admin on Fri Dec 15 16:04:20 GMT 2023
|
PRIMARY | |||
|
DBSALT000017
Created by
admin on Fri Dec 15 16:04:20 GMT 2023 , Edited by admin on Fri Dec 15 16:04:20 GMT 2023
|
PRIMARY | |||
|
658552
Created by
admin on Fri Dec 15 16:04:20 GMT 2023 , Edited by admin on Fri Dec 15 16:04:20 GMT 2023
|
PRIMARY | RxNorm | ||
|
190786-44-8
Created by
admin on Fri Dec 15 16:04:20 GMT 2023 , Edited by admin on Fri Dec 15 16:04:20 GMT 2023
|
PRIMARY | |||
|
164521
Created by
admin on Fri Dec 15 16:04:20 GMT 2023 , Edited by admin on Fri Dec 15 16:04:20 GMT 2023
|
PRIMARY | |||
|
SUB22587
Created by
admin on Fri Dec 15 16:04:20 GMT 2023 , Edited by admin on Fri Dec 15 16:04:20 GMT 2023
|
PRIMARY | |||
|
6W18MO1QR3
Created by
admin on Fri Dec 15 16:04:20 GMT 2023 , Edited by admin on Fri Dec 15 16:04:20 GMT 2023
|
PRIMARY | |||
|
31281
Created by
admin on Fri Dec 15 16:04:20 GMT 2023 , Edited by admin on Fri Dec 15 16:04:20 GMT 2023
|
PRIMARY | |||
|
CHEMBL1201758
Created by
admin on Fri Dec 15 16:04:20 GMT 2023 , Edited by admin on Fri Dec 15 16:04:20 GMT 2023
|
PRIMARY | |||
|
6W18MO1QR3
Created by
admin on Fri Dec 15 16:04:20 GMT 2023 , Edited by admin on Fri Dec 15 16:04:20 GMT 2023
|
PRIMARY | |||
|
100000086310
Created by
admin on Fri Dec 15 16:04:20 GMT 2023 , Edited by admin on Fri Dec 15 16:04:20 GMT 2023
|
PRIMARY | |||
|
C83550
Created by
admin on Fri Dec 15 16:04:20 GMT 2023 , Edited by admin on Fri Dec 15 16:04:20 GMT 2023
|
PRIMARY | |||
|
m2421
Created by
admin on Fri Dec 15 16:04:20 GMT 2023 , Edited by admin on Fri Dec 15 16:04:20 GMT 2023
|
PRIMARY | Merck Index |
ACTIVE MOIETY
SUBSTANCE RECORD